Amicus Therapeutics is an American biopharmaceutical organization that is based in Cranbury, New Jersey. In 2007, this organization went public with FOLD being the NASDAQ trading symbol. They have been and still are focused mainly on the rare and orphan diseases, especially lysomal storage disorders (LSD). Their groundbreaking product development is largely based on the Chaperone-Advanced Replacement Therapy (CHART) platform. Also, Amicus Therapeutics is concentrated on enzyme replacement therapies (ERTs) development.
Before this company became public, various venture capital organizations funded them, including Canaan Partners, New Enterprise Associates, and Radius Ventures (https://seekingalpha.com/article/4073303-amicus-therapeutics-small-biotech-seems-big-mo). Also, Amicus Therapeutics uses an outside contractor for manufacturing. Other historical events of this organization are as follows:
-In 2008, a second research site for them opened in San Diego, California.
-In late 2009, this organization endured a major financial loss with the dissolving of the multiyear agreement with Shire.
-In 2010, they received a US grant costing $500,000 from The Michael J. Fox Foundation in support of conducted studies with the David Geffen School of Medicine located at the University of California in Los Angeles.
-In November 2013, Amicus Therapeutics acquired Callidus Biopharma, their competitor, thus obtaining intellectual property and proprietary materials for the Pompe’s enzyme replacement therapy treatment.
-In September 2015, Amicus Therapeutics acquired Scioderm for around $947 million.
John F. Crowley has been serving as the chief executive officer since 2005. He also succeeded Donald Hayden, JR, to be the chairman of the board. Hayden, JR became the Lead Independent Director for the company. The chief operating officer is Bradley L. Campbell, and the chief financial officer is William D. Baird III. David Lockart was their chief scientific officer. And the the Director of Exploratory Biology’s position was held by Brandon Wustman beginning in 2010.
More about Amicus Therapeutics on Facebook